These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25515972)

  • 41. Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
    Kawai T; Kochi M; Fujii M; Song K; Hagiwara K; Watanabe M; Matsuno Y; Suda H; Yagi R; Takayama T
    Anticancer Res; 2017 Jun; 37(6):3301-3306. PubMed ID: 28551681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma.
    Xu XL; Yu HQ; Hu W; Song Q; Mao WM
    PLoS One; 2015; 10(9):e0138657. PubMed ID: 26390126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma.
    Ohira M; Kubo N; Masuda G; Yamashita Y; Sakurai K; Toyokawa T; Tanaka H; Muguruma K; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):4897-901. PubMed ID: 26254385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic inflammatory response and survival in patients undergoing curative resection of oral squamous cell carcinoma.
    Farhan-Alanie OM; McMahon J; McMillan DC
    Br J Oral Maxillofac Surg; 2015 Feb; 53(2):126-31. PubMed ID: 25440150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy.
    Karimata H; Shimoji H; Nishimaki T
    Surg Today; 2015 Apr; 45(4):479-86. PubMed ID: 25059344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
    Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
    Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Glasgow Prognostic Score. An useful tool to predict survival in patients with advanced esophageal squamous cell carcinoma.
    Henry MA; Lerco MM; de Oliveira WK; Guerra AR; Rodrigues MA
    Acta Cir Bras; 2015 Aug; 30(8):580-5. PubMed ID: 26352339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
    Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
    Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy.
    Miyata H; Yamasaki M; Makino T; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    J Surg Oncol; 2015 Jul; 112(1):60-5. PubMed ID: 26179950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after radical resection of esophageal squamous cell carcinoma].
    Chen H; He J
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):294-7. PubMed ID: 24989917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.
    Gockel I; Dirksen K; Messow CM; Junginger T
    World J Gastroenterol; 2006 Jun; 12(23):3746-50. PubMed ID: 16773693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma.
    Kijima T; Arigami T; Uchikado Y; Uenosono Y; Kita Y; Owaki T; Mori S; Kurahara H; Kijima Y; Okumura H; Maemura K; Ishigami S; Natsugoe S
    Cancer Sci; 2017 Feb; 108(2):193-199. PubMed ID: 27889946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
    Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.